BroadOak Capital Partners is a life sciences-focused boutique financial institution providing direct investment through BroadOak Asset Management and investment banking services through BroadOak Partners. The firm focuses on growth capital investments in life sciences tools, diagnostics, and biopharma services companies.
They made 2 investments in the last 12 months. Average disclosed round size is $8.0M (across 6 rounds with reported amounts).
Portfolio
7
Fund Size
$200M
Top Stage
Series C
Last 12 Mo
2
Team
AD
Austin Duke
Managing Director
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
7 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Axol Bioscience | Unknown | $2.8M | Jan 2026 |
| CCodis | Growth | — | Oct 2025 |
| KKROMATID | Series C | $8M | Aug 2025 |
 PBS Biotech | Unknown | $22M | Jan 2023 |
| SSeqWell, Inc | Series C | $7M | Jan 2022 |
| HHalo Labs | Series B | $5.6M | Jan 2019 |
| BBiocision | Growth | $2.5M | Dec 2012 |
Top Co-Investors
Last updated: 14 September 2026